Myriad Genetics Corporate Presentation

01/09/2017

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

Our vision...

A trusted advisor transforming patients' lives worldwide with pioneering molecular diagnostics



The global leader in personalized medicine





Answering patients' **four** most pressing questions


Will I get a disease? Do I have a disease? Should I treat this disease? How should I treat this disease?

In **six** medical specialties

Oncology Dermatology Preventive Care Autoimmune Urology Neuroscience

Diagnostics Are the Keystone for Personalized Medicine

Focused on Six Medical Specialties with Over \$200B in Waste



*Eliminating Waste in U.S. Healthcare **Clinical Lab Products Magazine – "The Value of Diagnostics"

Myriad Leads Personalized Medicine Industry

Unique Scale and Expertise Creates Sustainable Competitive Advantage

1 only profitable R&D driven personalized medicine company

2.5 million tests performed; unmatched reputation for quality
2,500 employees dedicated to the Myriad mission
>1,000 scientific publications to date; extensive research capabilities


3 expertise with all three types of biomarkers (DNA, RNA, and proteins)

1 only personalized medicine company with broad regulatory experience

>90,000 ordering physicians since inception; deep relationships 95% of payers with Myriad is an in-network provider



Strategic Imperatives to Achieve Our Goals








Continued Leadership in an Expanding Hereditary Cancer Market

Diversify Revenue With New Products Grow Kit Products in Major International Geographies

Strategic Imperatives to Achieve Our Goals







Continued Leadership in an Expanding Hereditary Cancer Market


Diversify Revenue With New Products Grow Kit Products in Major International Geographies



Quality Hereditary Cancer Testing Saves Lives Can Reduce Cancer Risks by >90%

- Deleterious mutations lead to up to a 7-fold risk of breast cancer and up to a 16-fold risk of colorectal cancer
- ≈15M adults in United States qualify for hereditary cancer testing; less than 10% have been tested
- Cost effective interventional steps can reduce lifetime risk to below the general population risk

National Cancer Institute; Surgery to Reduce Risk of Breast Cancer Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria.



Population Risk

Risk With Hereditary Cancer Mutation

Risk After Intervention



• In network with 95% of commercial payers; 65% under long-term, fixed-price contracts




Hereditary Cancer Revenue (in mil.)

*Based on analyst consensus estimates



A Market that Demands Perfection

Three Competitive Advantages Provide Important Differentiation



Lab accuracy:

- 85,000 base pairs with 100% accuracy
- 856 steps using 23 major technology platforms
- 100 proprietary software applications

Variant classification:


- 20 years of research; > \$100M investment
- >2.5M patients tested; 50k variants identified
- 5 proprietary methods with 99.5% validity

Customer service & support:

- Over 40k ordering physicians annually
- 450 field educators
- Extensive reimbursement support
- Lifetime commitment to patients




Substantial Opportunity for Volume Growth New Indications Can Double Market Potential for Hereditary Cancer





Pricing and Cost Bands for Hereditary Cancer Panels Myriad Quality Justifies Significant Price Premium



*Association for Molecular Pathology micro-costing analysis

Strategic Imperatives to Achieve Our Goals







Continued leadership in an Expanding Hereditary Cancer Market

Diversify Revenue With New Products

Grow Kit Products in Major International Geographies



Industry Leading Pipeline Sold Through Multiple Channels Generating Commercial Leverage

Industry Leading Pipeline Sold Through Multiple Channels Generating Commercial Leverage					
		Discovery	Validation	Reimbursement	Adoption
	TAM	Stage 1	Stage 2	Stage 3	Stage 4
myRisk Hereditary Cancer*	\$5B				
GeneSight*	\$4B				
Vectra DA*	\$3B				
Prolaris*	\$1.5B				
EndoPredict*	\$0.7B				
myChoice HRD	\$6B				
myPath Melanoma	\$0.8B				
myPlan Lung Cancer	\$0.2B				
myPlan Renal Cancer	\$0.4B				
myPath Bipolar	\$5B				
myPath Endometriosis	\$3B				
myPath Psoriatic Arthritis	\$3B				

Autoimmune

Dermatology

Neuroscience

Urology

* Revenue Generation

Oncology

Preventive Care






Value Proposition for Pipeline Products Total Addressable Market >\$25B Opportunity

Product	Indication	Utility	Global TAM
MYRIAD Risk® Hereditary Cancer	Personal or family history of cancer	Reduces cancer risk by 90%	\$5 billion
genesight	Treatment resistant depression	Improves response to psychotropic drugs	\$4 billion
Vectra DA	Rheumatoid arthritis (RA)	Predicts disease progression to optimize drug treatment	\$3 billion
Prolaris [.]	Prostate cancer	Identifies patients that can pursue active surveillance	\$1.5 billion
Endo Predict [®]	ER+ breast cancer	Identifies patients that can forgo chemotherapy	\$0.7 billion
my Choice	Cancers caused by DNA repair defects	Predicts responders to DNA damaging agents	\$6 billion
MYRIAD Path	Suspicious skin lesions	Differentiates melanoma from benign lesions with >90% accuracy	\$0.8 billion
	Early stage lung cancer	Identifies patients that can benefit from chemotherapy	\$0.2 billion




Substantial Diversification in Testing Volumes

≈ Two-Thirds of Volume Generated by New Products





Current Revenue Run Rate at Full Reimbursement





Myriad Portfolio Offers Unprecedented Payer Economics Large Payer Can Save >\$200M per year

			Est. Gross Savings (including test costs)
Product	Indication	Value Driver	2017
EndoPredict	Breast cancer recurrence testing	Avoid unnecessary chemotherapy and reduce unit cost of testing.	\$0.11 PMPM
VectraDA	Rheumatoid arthritis biomarker	Require biomarker results before biologic use in methotrexate non-responders.	\$0.20 PMPM
GeneSight	Pharmacogenomic testing for depression & anxiety	More efficient spending on psychotropic drugs and lower healthcare utilization.	\$0.06 PMPM
Prolaris	Prostate cancer testing	Require test results in NCCN® low- and favorable intermediate-risk Prostate Cancer; appropriately reduce surgical and radiation therapies.	\$0.19 PMPM

\$0.51 PMPM

Myriad can save a large / payer >\$200M per year



Companion Diagnostics Represent Near-Term Opportunity >\$1B 10 Pivotal Clinical Studies Report in Next 18 Months

Indication	Number of Studies	First Data Expected	Total Patients
HER2- metastatic breast cancer	4	Mar. 2017	160,000
Neoadjuvant TNBC	2	Mar. 2017	70,000
Other ovarian	3	Mar. 2017	50,000
Pancreatic	1	Dec. 2017	100,000

380,000

Strategic Imperatives to Achieve Our Goals








Continued leadership in an Expanding Hereditary Cancer Market

Diversify Revenue With New Products Grow Kit Products in Major International Geographies



Total Available Market (TAM) in 10 Major International Markets > U.S.






International Growth Focused in Major Geographies Kit Products Appeal to Existing Business Models

Near- TermEU5 + CanadaRNA• EndoPredict • Prolaris	
Growth: (platform partner): • myPlan Lung • myPath Melanoma	^{MYRIAD} Risk [™]
Long- Term Growth:Japan, China, and BrazilProtein (platform partner):• Vectra DA • myPath Bipolar • myPath Pancreatic(multip platfor	



International Contribution Growing Rapidly

More Than 6x Increase Since Launch



Financial Outlook








Historical Financial Performance Strong Track Record of Revenue and Operating Income Growth




Historical Operating Income



Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.




One Path To Achieving 10% Revenue CAGR Full Reimbursement and Modest Growth





Profitability Benefits From Significant Leverage Additional Reimbursement + Volume Growth Through Existing Sales Channels





Uses of Cash

Uses of Cash	Current Focus	GOAL
R&D	9% of revenue	Invest in late stage reimbursement studies
M&A	Integration of Assurex and Sividon Acquisitions	 Pay \$200M in milestones due next two years Assess opportunities that fit 4in6 strategy with potential for near-term accretion
Debt Repayment	\$200M	Reduce with excess free cash flow
Share Repurchase	\$174M authorized	Opportunistic open market purchases

Worldwide Leader in Personalized Medicine

- We are entering the golden age for personalized medicine
- Molecular diagnostics are the keystone for improving patient outcomes while eliminating waste in healthcare spending
- Myriad is the pioneer of "research-based" and "education-centric" business model for molecular diagnostics
- We are the best positioned company to lead this revolution in healthcare

